Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2007

BioFocus DPI and AstraZeneca Sign Second Discovery Transaction

  • BioFocus DPI entered into a drug discovery collaboration with AstraZeneca. This is the second program between the two companies after the August 2006 agreement.

    In this new deal, BioFocus DPI will perform medicinal chemistry, computational chemistry, and supporting biology and ADME-Tox services for an AstraZeneca drug discovery program. Total contract value for Galapagos is Euro 620,000.

    "We have been pleased with the level of progress thus far and expect that BioFocus DPI's expanded ADMET and predictive drug discovery capabilities will be key contributors in advancing this hit-to-lead program," says Lars-Erik Arvidsson, vp, head of respiratory research, AstraZeneca R&D Lund.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »